https://www.dana-farber.org/clinical-trials/20-166
This research study involves testing the safety and efficacy of an investigational intervention for patients with triple-negative breast cancer (TNBC) that has...
phase ii studysacituzumab govitecaniotnbcrandomized
https://www.gilead.com/news/news-details/2021/everest-medicines-and-gilead-sciences-jointly-announce-phase-2b-study-of-sacituzumab-govitecan-conducted-in-china-of-patients-with-metastatic-triple-negative-breast-cancer-meets-primary-over
Everest Medicines and Gilead Sciences Jointly Announce Phase 2b Study of Sacituzumab Govitecan Conducted in China of Patients With Metastatic Triple Negative...
gilead scienceseverestmedicinesjointlyannounce
https://www.openpr.com/news/2470922/sacituzumab-govitecan-shows-promise-in-treating-the-most
Press release - Biochempeg Scientific Inc. - Sacituzumab govitecan shows promise in treating the most aggressive type of breast cancer - published on openPR.com
sacituzumab govitecanshowspromisetreating